News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions


6/17/2014 9:00:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Copenhagen, 17 June 2014 – Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) provides a summary of new clinical data and information presented on Lyxumia® (lixisenatide) and on LixiLan, the fixed-ratio combination of Lyxumia® with Lantus®, during the American Diabetes Association’s 74th Scientific Sessions, held in San Francisco, 13 – 17 June 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES